Marksans Pharma Ltd

Marksans Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Marksans Pharma Ltd

₹ 309 -0.16%
22 Nov - close price
marksanspharma.com BSE: 524404 NSE: MARKSANS
About

Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products.

Our key focus areas lie in the OTC & prescription drugs that have wide-ranging applications across fields like Oncology, Gastroenterology, Antidiabetic, Antibiotics, Cardiovascular, Pain Management, Gynaecology, among others. [1]

Key Points

Revenue Mix
Revenue Mix by therapeutic wise FY23[1]
Pain Management : 44%
Cough & Cold : 14%
Cardiovascular System : 9%
CNS: 8%
Anti-diabetic : 2%
Gastrointestinal : 9%
Others : 14%

Website BSE NSE
  • Market Cap ₹ 13,987 Cr.
  • Current Price ₹ 309
  • High / Low ₹ 329 / 126
  • Stock P/E 40.4
  • Book Value ₹ 50.3
  • Dividend Yield 0.19 %
  • ROCE 20.6 %
  • ROE 16.5 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company is almost debt free.

Cons

  • Promoter holding has decreased over last 3 years: -4.38%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Part of BSE Allcap Nifty Microcap 250 BSE Healthcare Nifty Total Market BSE SmallCap

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
361 363 418 434 453 480 486 500 531 586 560 591 642
301 305 354 361 372 403 376 398 417 453 450 462 506
Operating Profit 60 58 64 73 80 77 110 102 114 133 110 128 136
OPM % 17% 16% 15% 17% 18% 16% 23% 20% 21% 23% 20% 22% 21%
9 12 15 16 14 18 11 10 19 5 17 15 11
Interest 2 1 5 2 3 2 2 2 2 3 5 3 3
Depreciation 7 9 21 11 14 13 14 14 18 22 21 20 20
Profit before tax 60 60 53 76 78 79 104 97 114 113 100 120 125
Tax % 23% 20% 44% 21% 23% 21% 21% 27% 26% 26% 23% 26% 22%
46 48 30 60 60 62 83 70 84 83 78 89 98
EPS in Rs 1.11 1.18 0.69 1.46 1.51 1.57 1.81 1.52 1.84 1.84 1.73 1.96 2.13
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
438 630 797 893 767 913 1,000 1,134 1,376 1,491 1,852 2,177 2,379
369 512 612 757 722 834 868 942 1,037 1,232 1,513 1,719 1,872
Operating Profit 69 118 185 136 45 78 132 192 340 259 340 459 507
OPM % 16% 19% 23% 15% 6% 9% 13% 17% 25% 17% 18% 21% 21%
4 4 3 9 7 8 5 0 7 42 59 50 47
Interest 15 19 16 10 7 10 10 9 8 8 9 11 14
Depreciation 16 16 16 28 30 27 23 27 36 45 52 74 83
Profit before tax 44 86 156 107 15 50 104 157 302 248 338 424 458
Tax % -12% 15% 28% 23% 24% 28% 23% 23% 21% 25% 21% 26%
49 74 112 83 11 36 80 121 239 187 265 315 347
EPS in Rs 1.19 1.87 2.67 1.92 0.22 0.80 1.87 2.95 5.76 4.51 5.88 6.92 7.66
Dividend Payout % 10% 5% 4% 21% 23% 6% 3% 3% 4% 6% 9% 9%
Compounded Sales Growth
10 Years: 13%
5 Years: 17%
3 Years: 17%
TTM: 19%
Compounded Profit Growth
10 Years: 16%
5 Years: 33%
3 Years: 10%
TTM: 17%
Stock Price CAGR
10 Years: 18%
5 Years: 83%
3 Years: 76%
1 Year: 118%
Return on Equity
10 Years: 18%
5 Years: 20%
3 Years: 18%
Last Year: 16%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 39 39 41 41 41 41 41 41 41 41 45 45 45
Reserves 34 90 326 401 392 430 502 595 846 1,068 1,700 2,020 2,236
176 173 101 100 110 118 100 30 34 111 123 244 198
152 188 207 180 209 142 160 236 307 416 322 372 432
Total Liabilities 401 490 676 722 752 731 802 902 1,228 1,636 2,190 2,681 2,911
156 146 166 270 267 279 270 303 309 428 486 776 787
CWIP -0 -0 -0 -0 0 -0 -0 -0 12 3 10 9 11
Investments -0 -0 -0 -0 -0 -0 -0 -0 0 0 1 27 15
245 344 510 452 484 451 533 599 907 1,205 1,694 1,869 2,098
Total Assets 401 490 676 722 752 731 802 902 1,228 1,636 2,190 2,681 2,911

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
39 65 155 31 14 50 27 233 179 99 237 230
-5 -4 -33 -123 -21 -39 -13 -60 -45 -84 -259 -141
-40 -29 17 -58 -3 3 -21 -114 -15 80 198 -69
Net Cash Flow -7 31 138 -150 -10 15 -7 60 118 94 176 21

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 109 98 84 89 118 71 64 78 72 97 82 76
Inventory Days 112 102 107 120 151 152 215 155 248 216 192 217
Days Payable 81 83 88 85 129 54 78 71 103 102 91 94
Cash Conversion Cycle 141 118 103 124 140 169 202 163 217 211 183 199
Working Capital Days 37 48 55 95 130 117 133 94 110 138 133 138
ROCE % 43% 37% 44% 23% 4% 10% 18% 25% 38% 23% 22% 21%

Shareholding Pattern

Numbers in percentages

5 Recently
Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
48.25% 48.25% 48.25% 48.60% 49.00% 43.85% 43.85% 43.85% 43.85% 43.85% 43.87% 43.87%
2.59% 3.46% 4.04% 4.06% 4.23% 15.11% 14.90% 15.07% 15.55% 15.57% 18.59% 21.31%
0.41% 0.47% 0.94% 0.95% 0.96% 1.46% 3.65% 4.02% 4.76% 5.17% 3.75% 4.10%
48.75% 47.82% 46.77% 46.38% 45.79% 39.57% 37.60% 37.06% 35.81% 35.40% 33.77% 30.70%
No. of Shareholders 2,14,9982,20,0902,21,3592,17,7432,13,1231,98,3821,88,4472,07,9372,37,3772,54,6992,35,5002,48,845

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls